CancerNCT05940753
Flash Mob Study With Regard to Travel Willingness Among Patients With Cancer
An observational study of Cancer, run by University Medical Center Groningen at 1 site in Netherlands.
Trial summary
This is a cross-sectional study in the form of a flash mob study, in which an inventory will be made on 13 and 14 March 2023 of the willingness to travel of oncology patients in the participating hospitals. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- What is being tested?
- Survey about travel willingness regarding cancer treatment and follow-up
- How many people
- 5,000 participants
- Where
- 1 siteNetherlands
- Study dates
- 13 Mar 2023to 1 May 2023
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Medical Oncology patients who have an (call) appointment with our medical oncology outpatient clinic and/or day treatment unit on 13 or 14 march 2023.
Who may be able to join
- Medical oncology patients with an appointment in the out-patient clinic or day treatment unit on 13 or 14 march 2023
- Medical oncology patients with an (video) call appointment in the out-patient clinic on 13 or 14 march 2023
Who cannot join
- Patients in the inpatients oncology unit
- Medical oncology patients with no appointment on 13 or 14 march 2023
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Flashmobstudie Landelijke Meting Reisbereidheid Medisch Oncologische Zorg
This is a cross-sectional study in the form of a flash mob study, in which an inventory will be made on 13 and 14 March 2023 of the willingness to travel of oncology patients in the participating hospitals. Patients who have an appointment with an internist-oncologist or oncology specialist nurse at the outpatient clinic or by telephone and patients who come to day treatment unit for medical oncology are asked to participate. Willingness to travel is examined by means of a survey, in which a minimal set of categorized patient data (e.g. age, gender, level of education) is collected as part of the survey.
- Conditions
- Cancer
- Being tested
- Survey about travel willingness regarding cancer treatment and follow-up
- Keywords
- oncology, hospital choice, willingness to travel
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Survey about travel willingness regarding cancer treatment and follow-upOther
No intervention. Willingness to travel is examined through a survey. The survey will be conducted digitally, but may also be done on paper. In the survey a minimal set of categorized patient data (e.g. age, gender, level of education) is collected as part of the survey. For patients who cannot independently complete the questionnaire (for example due to low literacy skills), a volunteer, medical student or researcher is allowed to help the patient.
| Study group | Role | What they receive |
|---|---|---|
| Cohort: medical oncology patients in the out-patient clinic or treatment unit on 13 or 14 march 2023 | No interventions. Receives: Other: Survey about travel willingness regarding cancer treatment and follow-up |
What is being measured
The primary outcome is the main question the study is designed to answer.
Travel willingness
How far is the oncological patient willing to travel for his/her systemic treatment or follow-up?
Measured: 1 day
Secondary outcomes (2)
Facilitating and inhibiting factors for willingness to travel
What are facilitating and inhibiting factors in patients' willingness to travel?
Measured: 1 day
Which patient characteristics are associated with willingness to travel?
Which patient characteristics are associated with willingness to travel? (age, type of cancer, curative/palliative treatment, distance to nearest hospital)
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jul 2023
- Study start13 Mar 2023
- Primary completion1 May 2023
- Study completion1 May 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by University Medical Center GroningenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 5,000 participants (actual)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- University Medical Center Groningen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- An KL Reyners, MD, PhD, Principal investigator, University Medical Center Groningen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05940753
- Sponsor's protocol ID
- 15954
- Status last verified
- Jul 2023
- First submitted
- 20 Mar 2023
- Last updated
- 11 Jul 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 11 Jul 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Flashmobstudie Landelijke Meting Reisbereidheid Medisch Oncologische Zorg
- ClinicalTrials.gov ID
- NCT05940753
- Acronym / sponsor ID
- 15954
- Conditions
- Cancer
- Keywords
- oncology, hospital choice, willingness to travel
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 5,000 participants (actual)
- Lead sponsor
- University Medical Center GroningenUniversity, hospital or other
- Study start
- 13 Mar 2023 (actual)
- Primary completion
- 1 May 2023 (actual)
- Study completion
- 1 May 2023 (actual)
- First posted
- 11 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a cross-sectional study in the form of a flash mob study, in which an inventory will be made on 13 and 14 March 2023 of the willingness to travel of oncology patients in the participating hospitals. Patients who have an appointment with an internist-oncologist or oncology specialist nurse at the outpatient clinic or by telephone and patients who come to day treatment unit for medical oncology are asked to participate. Willingness to travel is examined by means of a survey, in which a minimal set of categorized patient data (e.g. age, gender, level of education) is collected as part of the survey.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Day
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cohort: medical oncology patients in the out-patient clinic or treatment unit on 13 or 14 march 2023 | – | Other: Survey about travel willingness regarding cancer treatment and follow-upNo interventions. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Medical Oncology patients who have an (call) appointment with our medical oncology outpatient clinic and/or day treatment unit on 13 or 14 march 2023.
Key inclusion criteria (2 listed)
- Medical oncology patients with an appointment in the out-patient clinic or day treatment unit on 13 or 14 march 2023
- Medical oncology patients with an (video) call appointment in the out-patient clinic on 13 or 14 march 2023
Key exclusion criteria (2 listed)
- Patients in the inpatients oncology unit
- Medical oncology patients with no appointment on 13 or 14 march 2023
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Survey about travel willingness regarding cancer treatment and follow-upNo intervention. Willingness to travel is examined through a survey. The survey will be conducted digitally, but may also be done on paper. In the survey a minimal set of categorized patient data (e.g. age, gender, level of education) is collected as part of the survey. For patients who cannot independently complete the questionnaire (for example due to low literacy skills), a volunteer, medical student or researcher is allowed to help the patient. | Other | Cohort: medical oncology patients in the out-patient clinic or treatment unit on 13 or 14 march 2023 |
Primary outcome
Travel willingness
Time frame: 1 day
How far is the oncological patient willing to travel for his/her systemic treatment or follow-up?
2 secondary outcomes
Facilitating and inhibiting factors for willingness to travel
Time frame: 1 day
Which patient characteristics are associated with willingness to travel?
Time frame: 1 day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jul 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
An KL Reyners, MD, PhD principal investigator
University Medical Center Groningen
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by University Medical Center Groningen at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Travel willingness (time frame: 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2023.